Having evaluated the platform, the Beckman Research Institute of City of Hope now plans to integrate the technology into its workflow to manufacture investigational CAR-T cell immunotherapy.
It is the first of the company’s technology access program collaborators to formally integrate the Curate Cell Processing System in this manner. Industry and academic players have been testing the system, under non-disclosure.
“This particular investigator – City of Hope - is working on T cell therapies to address infectious disease, specifically HIV. Unbiased, high-efficiency cell recovery ensures that there is maximal recovery of the specific T cells required for our collaborators' therapeutic approach.
"And since the initial steps for autologous therapies are similar, regardless of therapeutic application, the Curate system is an appropriate solution for both cancer and non-oncology cell therapy applications, from HIV to autoimmune disorders,” Joan Haab, senior vice president, manufacturing and supply chain operations, told BioPharma-Reporter.
The use of Curate’s system in the therapeutic manufacturing workflow maximizes recovery of a patient’s white blood cells to be used in producing the cell therapy, she continued. “Through gentle processing with the closed Curate system, the City of Hope team can protect cellular health, ensuring isolated cells have maximal viability while reducing the risk of contamination or sample loss. And because it's automated, processing time is short and will not require highly skilled labor to execute."
"processing" - Google News
April 05, 2022 at 10:34PM
https://ift.tt/yExP9Jv
US cancer research institute validates Curate's cell processing system - BioPharma-Reporter.com
"processing" - Google News
https://ift.tt/pKnCUA4
https://ift.tt/NeQbip2
Bagikan Berita Ini
0 Response to "US cancer research institute validates Curate's cell processing system - BioPharma-Reporter.com"
Post a Comment